Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | BRD2 | P25440 | 1/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899308 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL24512246 | 0.87 | CNR1 (0.46) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL29717111 | 0.86 | CNR1 (0.64) | KDM4EALDH1A1MAPK1SMN1; SMN2BRD4 | |
| SCHEMBL24512245 | 0.86 | CNR1 (0.64) | KDM4EALDH1A1MAPK1SMN1; SMN2BRD4 | |
| SCHEMBL24512267 | 0.84 | ALDH1A1 (0.56) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL30899273 | 0.84 | ALDH1A1 (0.56) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL30899304 | 0.82 | KMT2A (0.50) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL24512335 | 0.82 | KMT2A (0.50) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL24512119 | 0.81 | GAA (0.46) | KDM4EALDH1A1GAAMAPK1SMN1; SMN2 | |
| SCHEMBL24512144 | 0.81 | CNR1 (0.60) | KDM4EALDH1A1MAPK1SMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | KDM4E 3428/4885ALDH1A1 322/4885GAA 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.